What is marginal zone lymphoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Marginal Zone Lymphoma?

Marginal zone lymphoma (MZL) is an indolent B-cell non-Hodgkin lymphoma arising from marginal zone B cells within lymphoid follicles, representing approximately 5-15% of all non-Hodgkin lymphomas in the Western world 1.

Classification and Subtypes

MZL encompasses three distinct anatomical subtypes, each with unique clinical characteristics:

  • Extranodal MZL (EMZL): Comprises approximately two-thirds of all MZL cases. Also known as MALT (mucosa-associated lymphoid tissue) lymphoma, it can arise at any extranodal site. The stomach is the most common location, followed by ocular adnexa, lung, and salivary glands 1.

  • Splenic MZL (SMZL): Accounts for approximately 20% of MZL cases 1.

  • Nodal MZL (NMZL): Represents less than 10% of cases 1.

Pathogenesis and Etiology

A defining feature of MZL is its frequent association with chronic antigenic stimulation from infections or autoimmune disorders 1. The disease typically develops in the context of:

  • Chronic infections (Helicobacter pylori in gastric EMZL, hepatitis C virus, Campylobacter jejuni, Chlamydia psittaci, Borrelia burgdorferi)
  • Autoimmune conditions
  • Persistent inflammatory states

This chronic stimulation promotes ectopic lymphoid tissue development and sustained B-cell activation, eventually leading to lymphomagenesis through additional oncogenic events 2.

Morphology and Immunophenotype

Cellular Characteristics

The typical marginal zone B cells are small- to medium-sized with:

  • Slightly irregular nuclei
  • Inconspicuous nucleoli
  • Moderately dispersed chromatin
  • Pale cytoplasm (may appear monocytoid) 1

Diagnostic Immunohistochemistry

Diagnosis requires immunohistochemistry with at least CD20, CD10, CD5, CD23, cyclin D1, immunoglobulin D, and SOX-11 1. The characteristic immunophenotype is:

  • CD20: Positive (mandatory)
  • CD5: Negative (mandatory)
  • CD10: Negative (mandatory)
  • Cyclin D1: Negative (mandatory)
  • CD23: Variable
  • MYD88 mutation: Typically negative 1

Critical Diagnostic Caveat

All diagnostic and follow-up biopsies should be reviewed by an expert hematopathologist 1. Transformation to large B-cell lymphoma is diagnosed when clearly separated sheets of large cells comprise more than 20% of the neoplastic population 1.

Clinical Behavior

MZL is characterized by:

  • Indolent clinical course in most cases
  • Heterogeneous behavior depending on anatomical site and molecular characteristics
  • Potential for transformation to aggressive lymphoma (though uncommon)
  • Site-specific progression patterns influenced by genetic and geographical factors 1

Key Distinguishing Features by Subtype

EMZL Specifics

  • Lymphoepithelial lesions are neither essential nor absolutely specific for diagnosis 1
  • In gastric cases, H. pylori status must be confirmed by histochemistry, serology, urea breath test, or stool antigen test 1
  • FISH for t(11;18)(p21;p21) helps identify patients unlikely to respond to antibiotic therapy 1

SMZL Specifics

  • Can often be diagnosed without splenectomy using peripheral blood/bone marrow morphology, flow cytometry, and bone marrow biopsy 1
  • Neoplastic lymphocytes may display villi (though not always present or visible) 1

NMZL Specifics

  • Shares morphological and immunophenotypic similarities with other MZL subtypes but requires differentiation from other indolent lymphomas 1

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.